Satisfaction of treatment with biologics is high in psoriasis: results from the Bio-CAPTURE network (pages 1158–1165)
J.M.P.A. van den Reek, P.P.M. van Lüumig, M.E. Otero, J. Zweegers, P.C.M. van de Kerkhof, P.M. Ossenkoppele, M.D. Njoo, J.M. Mommers, M.I.A. Koetsier, W.P. Arnold, B.A.M. Sybrandy-Fleuren, A.L.A. Kuijpers, M.P.M. Andriessen, M.M.B. Seyger, W. Kievit and E.M.G.J. de Jong
Version of Record online: 19 MAY 2014 | DOI: 10.1111/bjd.12862
What's already known about this topic?
- Maximum satisfaction with medication is thought to be positively related to adherence, health-related quality of life and patients' preferences.
- As shown in cross-sectional research, patients' dissatisfaction with treatment plays an important role in psoriasis. Those receiving biologics are the most satisfied with treatment among patients with psoriasis.
- In an open-label extension trial with etanercept, significant improvement in the ‘global satisfaction’, ‘effectiveness’ and ‘convenience’ domains was achieved after 3 months of treatment.
What does this study add?
- A prospective, longitudinal study on satisfaction with etanercept, adalimumab and ustekinumab for patients with psoriasis in daily practice.
- Significantly improved satisfaction rates (using the Treatment Satisfaction Questionnaire for Medication) were achieved after 3 and 6 months. As reported by the patients, the ‘effectiveness’ and ‘convenience’ domains showed the most room for improvement.
- After 6 months, biologics-inexperienced patients scored significantly better on the ‘global satisfaction’ domain than experienced patients.
Vol. 170, Issue 6, 1382, Version of Record online: 19 JUN 2014